Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer

P. Bouchal, M. Dvořáková, T. Roumeliotis, Z. Bortlíček, I. Ihnatová, I. Procházková, JT. Ho, J. Maryáš, H. Imrichová, E. Budinská, R. Vyzula, SD. Garbis, B. Vojtěšek, R. Nenutil,

. 2015 ; 14 (7) : 1814-30. [pub] 20150422

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020857

Current prognostic factors are insufficient for precise risk-discrimination in breast cancer patients with low grade breast tumors, which, in disagreement with theoretical prognosis, occasionally form early lymph node metastasis. To identify markers for this group of patients, we employed iTRAQ-2DLC-MS/MS proteomics to 24 lymph node positive and 24 lymph node negative grade 1 luminal A primary breast tumors. Another group of 48 high-grade tumors (luminal B, triple negative, Her-2 subtypes) was also analyzed to investigate marker specificity for grade 1 luminal A tumors. From the total of 4405 proteins identified (FDR < 5%), the top 65 differentially expressed together with 30 previously identified and control markers were analyzed also at transcript level. Increased levels of carboxypeptidase B1 (CPB1), PDZ and LIM domain protein 2 (PDLIM2), and ring finger protein 25 (RNF25) were associated specifically with lymph node positive grade 1 tumors, whereas stathmin 1 (STMN1) and thymosin beta 10 (TMSB10) associated with aggressive tumor phenotype also in high grade tumors at both protein and transcript level. For CPB1, these differences were also observed by immunohistochemical analysis on tissue microarrays. Up-regulation of putative biomarkers in lymph node positive (versus negative) luminal A tumors was validated by gene expression analysis of an independent published data set (n = 343) for CPB1 (p = 0.00155), PDLIM2 (p = 0.02027) and RELA (p = 0.00015). Moreover, statistically significant connections with patient survival were identified in another public data set (n = 1678). Our findings indicate unique pro-metastatic mechanisms in grade 1 tumors that can include up-regulation of CPB1, activation of NF-κB pathway and changes in cell survival and cytoskeleton. These putative biomarkers have potential to identify the specific minor subpopulation of breast cancer patients with low grade tumors who are at higher than expected risk of recurrence and who would benefit from more intensive follow-up and may require more personalized therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020857
003      
CZ-PrNML
005      
20190204100030.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1074/mcp.M114.041335 $2 doi
035    __
$a (PubMed)25903579
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bouchal, Pavel, $7 xx0128495 $d 1975- $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Biochemistry, Brno, Czech Republic
245    10
$a Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer / $c P. Bouchal, M. Dvořáková, T. Roumeliotis, Z. Bortlíček, I. Ihnatová, I. Procházková, JT. Ho, J. Maryáš, H. Imrichová, E. Budinská, R. Vyzula, SD. Garbis, B. Vojtěšek, R. Nenutil,
520    9_
$a Current prognostic factors are insufficient for precise risk-discrimination in breast cancer patients with low grade breast tumors, which, in disagreement with theoretical prognosis, occasionally form early lymph node metastasis. To identify markers for this group of patients, we employed iTRAQ-2DLC-MS/MS proteomics to 24 lymph node positive and 24 lymph node negative grade 1 luminal A primary breast tumors. Another group of 48 high-grade tumors (luminal B, triple negative, Her-2 subtypes) was also analyzed to investigate marker specificity for grade 1 luminal A tumors. From the total of 4405 proteins identified (FDR < 5%), the top 65 differentially expressed together with 30 previously identified and control markers were analyzed also at transcript level. Increased levels of carboxypeptidase B1 (CPB1), PDZ and LIM domain protein 2 (PDLIM2), and ring finger protein 25 (RNF25) were associated specifically with lymph node positive grade 1 tumors, whereas stathmin 1 (STMN1) and thymosin beta 10 (TMSB10) associated with aggressive tumor phenotype also in high grade tumors at both protein and transcript level. For CPB1, these differences were also observed by immunohistochemical analysis on tissue microarrays. Up-regulation of putative biomarkers in lymph node positive (versus negative) luminal A tumors was validated by gene expression analysis of an independent published data set (n = 343) for CPB1 (p = 0.00155), PDLIM2 (p = 0.02027) and RELA (p = 0.00015). Moreover, statistically significant connections with patient survival were identified in another public data set (n = 1678). Our findings indicate unique pro-metastatic mechanisms in grade 1 tumors that can include up-regulation of CPB1, activation of NF-κB pathway and changes in cell survival and cytoskeleton. These putative biomarkers have potential to identify the specific minor subpopulation of breast cancer patients with low grade tumors who are at higher than expected risk of recurrence and who would benefit from more intensive follow-up and may require more personalized therapy.
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a nádory prsu $x genetika $x metabolismus $7 D001943
650    _2
$a karboxypeptidasa B $x metabolismus $7 D043424
650    _2
$a databáze proteinů $7 D030562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $x metody $7 D020869
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a izotopové značení $7 D007553
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a NF-kappa B $x metabolismus $7 D016328
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a proteomika $x metody $7 D040901
650    _2
$a reprodukovatelnost výsledků $7 D015203
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dvořáková, Monika $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Biochemistry, Brno, Czech Republic
700    1_
$a Roumeliotis, Theodoros $u Proteomics Mass Spectrometry, The Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK;
700    1_
$a Bortlíček, Zbyněk $u Masaryk University, Faculty of Medicine, Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Ihnatová, Ivana $u Masaryk University, Faculty of Medicine, Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Procházková, Iva $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
700    1_
$a Ho, Jenny T C $u ThermoFisher Scientific, Hemel Hempstead, UK
700    1_
$a Maryáš, Josef $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Biochemistry, Brno, Czech Republic
700    1_
$a Imrichová, Hana $u Laboratory of Computational Biology, Center for Human Genetics, University of Leuven, Belgium
700    1_
$a Budinská, Eva $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; Masaryk University, Faculty of Medicine, Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Vyzula, Rostislav $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
700    1_
$a Garbis, Spiros D $u University of Southampton, School of Medicine, Cancer Sciences Division, Institute for Life Sciences-Center for Proteomic Research, Southampton, UK
700    1_
$a Vojtěšek, Bořivoj $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
700    1_
$a Nenutil, Rudolf $u From the Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
773    0_
$w MED00007436 $t Molecular & cellular proteomics MCP $x 1535-9484 $g Roč. 14, č. 7 (2015), s. 1814-30
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25903579 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20190204100307 $b ABA008
999    __
$a ok $b bmc $g 1155527 $s 945385
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 14 $c 7 $d 1814-30 $e 20150422 $i 1535-9484 $m Molecular and cellular proteomics $n Mol Cell Proteomics $x MED00007436
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace